+49.0%
XEL vs GSK
+44.4%
+4.6%
-34.4%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 5y.
| Period | Portfolio | GSK | Excess | Alpha |
|---|---|---|---|---|
| 1D | +0.1% | +0.5% | -0.4% | 0.0% |
| 7D | +2.4% | +1.1% | +1.3% | +2.2% |
| 30D | +8.3% | +6.3% | +2.0% | +6.9% |
| 3M | +4.2% | +1.8% | +2.4% | +3.6% |
| 6M | +3.7% | +1.7% | +2.1% | +3.1% |
| YTD | +13.1% | +6.5% | +6.5% | +10.8% |
| 1Y | +5.0% | +9.5% | -4.5% | +2.3% |
| 3Y | +55.0% | +65.3% | -10.3% | +34.1% |
| All | +49.0% | +44.4% | +4.6% | +28.8% |
Cumulative growth
Daily Returns
Daily percentage return beside GSK.
Daily Out/Under-Performance
Portfolio return minus GSK return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × GSK return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 5y: compounded portfolio wealth divided by compounded GSK wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
5y analysis · Full analysis span regression · 6 months rolling